

Supplementary Table 1. Participant characteristics

	Oncologists (N = 15)
Years in practice, mean (range)	18 (4–26)
Specialty, n (%)	
Medical oncology	12 (80.0)
Medical oncology + hematology oncology	3 (20.0)
Number of new patients in prior month, mean (range)	13 (2–50)
Location, n (%)	
Urban	6 (40.0)
Suburban	8 (53.3)
Rural	1 (6.7)
Clinical setting, n (%)	
Academic	5 (33.3)
Nonacademic	10 (66.7)
Region, n (%)	
Northeast	4 (26.7)
South	6 (40.0)
Midwest	3 (20.0)
West	2 (13.3)
Sex, n (%)	
Male	11 (73.3)
Female	4 (26.7)

Supplementary Table 2. Ranking of belief statements for ordering biomarker tests

Belief Statement Domain	n^a	Frequency rank	Frequency score	Impact	Impact score	Conflict rank	Conflict score	Importance score
<i>I do/do not have complete knowledge of CLDN18.2 as a new actionable biomarker.</i> Knowledge	12	H	3	H	2	H	2	7
<i>I access credible knowledge sources to stay educated about biomarkers.</i> Knowledge	12	H	3	H	2	L	1	6
<i>Biomarker testing is/is not integrated into my EMR.</i> Environmental context	14	H	3	H	2	H	2	7
<i>I do/do not have the necessary support staff to help me with tasks related to biomarker testing.</i> Environmental context	12	H	3	H	2	H	2	7
<i>I do/do not feel that biomarker testing is urgent at the time of diagnosis.</i> Motivation, goals, priorities	13	H	3	H	2	H	2	7
<i>You're not doing your job if you don't order biomarker testing.</i> Social/professional role	11	H	3	H	2	L	1	6
<i>If I don't know biomarker test results, then I can't effectively treat the patient.</i> Beliefs about consequences	14	H	3	H	2	L	1	6

Frequency rank, H = 11–15; M = 6–10; L = 1–5; frequency score, H = 3; M = 2; L = 1; Impact on determining appropriate treatment, H/L; Impact score, H = 2; L = 1; Degree of conflicting beliefs, H/L; conflict score, H = 2; L = 1; importance score = total out of 7.

^aFrequency out of 15 respondents.

CLDN18.2, claudin 18 isoform 2; EMR, electronic medical record; H, high; L, low; M, medium.

Supplementary Table 3. Ranking of belief statements for determining appropriate treatment based on biomarker test results

<i>Belief Statement</i> Domain	n ^a	Frequency rank	Frequency score	Impact	Impact score	Degree of conflicting beliefs	Conflict score	Importance score
<i>I do/do not have incomplete knowledge around PD-L1 status and how to use it to make treatment decisions.</i> Knowledge	1	H	3	H	2	H	1	7
<i>When PD-L1 and CLDN18.2 are both expressed, I vary my approach to treatment depending on the patient.</i> Memory, attention, decision processes	8	M	2	H	2	H	2	6
<i>I do/do not struggle to interpret biomarker test results.</i> Skills	10	M	2	H	2	H	2	6

Frequency rank, H = 11–15; M = 6–10; L = 1–5; frequency score, H = 3; M = 2; L = 1; Impact on determining appropriate treatment, H/L; Impact score, H = 2; L = 1; Degree of conflicting beliefs, H/L; conflict score, H = 2; L = 1; importance score = total out of 7.

^aFrequency out of 15 respondents.

CLDN18.2, claudin 18 isoform 2; H, high; L, low; M, medium; PD-L1, programmed death-ligand 1.